{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-009611","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.995963+00:00","generated_at":"2026-05-15T09:13:53.493769+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NRx Pharmaceuticals stockholders approve increased evergreen share reserve cap at annual meeting","bullets":["Stockholder approved Amendment No. 1 to 2021 Omnibus Incentive Plan, effective March 23, 2026.","New annual share increase is lesser of 3,187,234 shares, 5% of outstanding, or Board-determined amount.","Class I directors Chaim Hurvitz and Michael Taylor re-elected with 9.86M and 9.89M For votes.","Appointment of Weinberg & Company as auditor ratified with 17.35M For (98.5% of votes cast).","Non-binding advisory vote on named executive officer compensation passed with 9.97M For."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-009611","json":"https://secwatch.observer/filing/0001437749-26-009611.json","markdown":"https://secwatch.observer/filing/0001437749-26-009611.md","text":"https://secwatch.observer/filing/0001437749-26-009611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926009611/0001437749-26-009611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926009611/nrxp20260324_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:13:53.493769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}